StemCells (STEM +2%) moves higher after announcing a conference call to discuss results from its...

|By:, SA News Editor

StemCells (STEM +2%) moves higher after announcing a conference call to discuss results from its Phase I clinical trial of HuCNS-SC - purified human neural stem cells used as a potential treatment for PMD, a rare hypo-myelination disorder in children.